Roche Gains Majority Stake In Foundation Medicine With R&D, Commercial Partnership
This article was originally published in The Gray Sheet
Executive Summary
Roche is investing up to $1.18 billion in the genomic analysis firm, inking a partnership focused on companion diagnostics, cancer drug development and expanded marketing of Foundation's novel sequencing-based platform.